Vet in Calgary Discusses Stem cell treatments in Pets
Stem Cell Regenerative Medicine uses the pet #39;s very own stem cells harvested by their own fat to treat diseases such as inflammatory arthritis, tendon injuries, bone diseases and degenerative...
By: Bow Bottom Veterinary Hospital
See the article here:
Vet in Calgary Discusses Stem cell treatments in Pets - Video
Stem cell regulations longevity
Stem cell regulations longevity.
By: Edouard Debonneuil
Read the original post:
Stem cell regulations & longevity - Video
Knee arthritis/torn meniscus 6 months after stem cell therapy by Dr Harry Adelson
Alan discusses his results six months after stem cell therapy by Dr Harry Adelson for treatment of his arthritic knees and torn menisci http://www.docereclinics.com.
By: Harry Adelson, N.D.
Excerpt from:
Knee arthritis/torn meniscus 6 months after stem cell therapy by Dr Harry Adelson - Video
This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE:
Xcelthera Inc and its joint research partner San Diego Regenerative Medicine Institute are granted U.S. Patent No. 8,716,017 entitled, Technologies, Methods, and Products of Small Molecule-Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells.
San Diego, CA (PRWEB) May 08, 2014
Xcelthera Inc, a major innovator in the stem cell research market and one of the first U.S. companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs, and its joint research partner San Diego Regenerative Medicine Institute announced today that the U.S. Patent and Trademark Office (USPTO) has granted Patent No. 8,716,017 entitled, Technologies, Methods, and Products of Small Molecule-Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells. This newly-issued patent is the first among a portfolio of intellectual property of Xcelthera Inc covering PluriXcel human stem cell technology platform for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart muscle cell therapy products.
Neurodegenerative and heart diseases are major health problems and cost the worldwide healthcare system more than $500 billion annually. The limited capacity of these two cell systems -- neurons and cardiomyocytes -- for self-repair makes them suitable for stem cell-based neuronal and heart therapies. Nevertheless, to date, the existing markets lack a clinically-suitable human neuronal cell source or cardiomyocyte source with adequate regenerative potential, which has been the major setback in developing safe and effective cell-based therapies for neurodegenerative and heart diseases. Xcelthera proprietary PluriXcel technology allows efficient derivation of clinical-grade human ES cell lines and direct conversion of such pluripotent human ES cells by small molecule induction into a large commercial scale of high quality human neuronal or heart muscle cells, which constitutes clinically representative progress in both human neuronal and cardiac therapeutic products for treating neurodegenerative and heart diseases.
PluriXcel technology of Xcelthera Inc is milestone advancement in stem cell research, offering currently the only available human cell therapy products with the pharmacological capacity to regenerate human neurons and contractile heart muscles that allow restitution of function of the central nervous system (CNS) and heart in the clinic. Through technology license agreement with San Diego Regenerative Medicine Institute, Xcelthera Inc has become the first in the world to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses.
As neurodegenerative and heart diseases incur exorbitant costs on the healthcare system worldwide, there is a strong focus on providing newer and more efficient solutions for these therapeutic needs. Millions of people are pinning their hopes on stem cell research. PluriXcel technology platform of Xcelthera Inc is incomparable, providing life scientists and clinicians with novel and effective resources to address major health concerns. Such breakthrough stem cell technology has presented human ES cell therapy derivatives as a powerful pharmacologic agent of cellular entity for a wide range of incurable or hitherto untreatable neurodegenerative and heart diseases. Introduction of medical innovations and new business opportunities based on PluriXcel technology will shape the future of medicine by providing pluripotent human ES cell-based technology for human tissue and function restoration, and bringing new therapeutics into the market.
About Xcelthera Inc.
Xcelthera INC (http://www.xcelthera.com) is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. The Company was recently incorporated in the state of California to commercialize the technologies and products developed, in part, with supports by government grants to the founder, by San Diego Regenerative Medicine Institute (SDRMI), an non-profit 501C3 tax-exempt status independent biomedical research institute that is interested in licensing its PATENT RIGHTS in a manner that will benefit the public by facilitating the distribution of useful products and the utilization of new processes, but is without capacity to commercially develop, manufacture, and distribute any such products or processes. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart muscle cell therapy products for commercial and therapeutic uses. The Company owns or has exclusive rights in a portfolio of intellectual property or license rights related to its novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Xcelthera breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs in world-wide major health problems. The Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding to raise fund for its pre-IPO business operation and filing confidential IPO as an emerging growth company according to the JOBS Act to create a public market for its common stock and to facilitate its future access to the public equity market and growth of the Company.
Originally posted here:
Xcelthera Inc Secures First U.S. Patent for Large-Scale Production of High Quality Human Embryonic Stem Cells and ...
Low back disc pain 3 months after stem cell therapy by Dr Harry Adelson
Brian discusses his results from the bone marrow stem cell injection into his lumbar discs performed by Dr Harry Adelson http://www.docereclinics.com.
By: Harry Adelson, N.D.
Excerpt from:
Low back disc pain 3 months after stem cell therapy by Dr Harry Adelson - Video
Treating Knee Osteoarthritis with Stem Cells - Dr. Ben Newton | Regenexx
Dr. Ben Newton discusses knee osteoarthritis and the use of stem cells for treating this common condition and avoiding knee replacement surgery. Regenexx off...
By: Regenexx
Read more from the original source:
Treating Knee Osteoarthritis with Stem Cells - Dr. Ben Newton | Regenexx - Video
How Stem Cells Decide Who to Be by Christina Jones
Part of the UW #39;s Engage Program, Christina Jones presented her PhD work on How Stem Cells Decide Who to Be. This talk was presented at Town Hall Seattle as part of the UW Science Now lecture...
By: Engage Science
See the original post here:
How Stem Cells Decide Who to Be by Christina Jones - Video
Mass. Scientists Develop Trachea Out Of Plastic, Stem Cells
The same technology is being used to build an artificial esophagus. WBZ-TV #39;s Dr. Mallika Marshall reports. Read more recent News stories: http://cbsboston.co...
By: CBS Boston
Continue reading here:
Mass. Scientists Develop Trachea Out Of Plastic, Stem Cells - Video
Acute torn meniscus; 5 months after stem cell therapy by Dr Harry Adelson
At Docere Clinics, the vast majority of cases we see are for chronic pain. Occasionally, we get acute injuries and do very well with them. Here, Bryan describes his experience 5 months after...
By: Harry Adelson, N.D.
Visit link:
Acute torn meniscus; 5 months after stem cell therapy by Dr Harry Adelson - Video
(PRWEB UK) 9 May 2014
Over the course of the human life span the body ages and becomes less able to repair itself, allowing it to become more prone to disease and illness. In the ever developing field of scientific discovery researchers have become intrigued with the concept of finding a way to slow down age-related diseases and prolonging life through the use of medicine. Since the Japanese scientist Shinya Yamanaka (http://bit.ly/1kWb20u) first discovered iPS cells in adult tissue and pioneered mature cell regeneration, this field in medicine has become one of the most rapidly developing fields in biomedicine.
A research team at the National Institute on Ageing at the National Institutes of Health in the US has discovered a promising strategy to arrest ageing by looking at a chemical called SRT1720 which activates a particular protein called Sirtuin 1 (SIRT1). Previous research has demonstrated that activating SIRT1 can have health benefits in various organisms, and it has been proposed as an anti-ageing protein. This study, published in the March edition of Research Journal: Cell (http://bit.ly/1od2gS5) focused on comparing the lifespan, health and diseases of mice fed the same diet, but with or without the addition of a SRT1720.
Overall they found mice fed a normal diet but with the supplement had a longer natural lifespan on average (about five weeks longer). During their lifetime, additional tests also suggested they had improved muscle function and coordination, improved metabolism, improved glucose tolerance, decreased body fat and cholesterol. All in all this suggests that giving the mice this supplement could protect them from the equivalent of metabolic syndrome, a series of risk factors associated with conditions such as heart disease and type 2 diabetes.
A study published today in the journal Stem Cell Reports (http://bit.ly/1hBSDF6) and carried out by the Spanish National Cancer Research Centre's Telomeres and Telomerase Group, reveals that the SIRT1 protein is needed to lengthen and maintain telomeres during cell reprogramming. SIRT1 also guarantees the integrity of the genome of stem cells that come out of the cell reprogramming process; these cells are known as iPS cells (induced Pluripotent Stem cells).
The nature of iPS cells, however, is causing intense debate. The latest research shows that chromosome aberrations and DNA damage can accumulate in these cells. "The problem is that we don't know if these cells are really safe," says Mara Luigia De Bonis, a postdoctoral researcher who has done a large part of the work. http://bit.ly/1m5gRgb
Researchers did not look at whether SIRT1 may cause side effects or complications so it is currently unclear whether SIRT1 would be safe in humans, let alone effective, but this interesting research has opened doors to pharmaceutical companies to develop dietary supplements that can help provide anti-aging pills, especially those who suffer hereditary degenerative diseases. These ongoing scientific studies will help shed light on how cell reprogramming guarantees the healthy functioning of stem cells. This knowledge will help to overcome barriers that come out of the use of iPS cells so they may be used in regenerative medicine.
Link:
Production of synthetic SIRT1 as a dietary supplement may help prolong life, states Chemist Direct
Purtier Placenta | Buy Genuine Product - President Obama on Live Stem Cells
Purtier Placenta | Buy Purtier Placenta Genuine Product - Go to http://patrickgan9.com for more updated information. President Obama on Live Stem Cells. Expl...
By: Patrickgan PurtierPlacenta
Visit link:
Purtier Placenta | Buy Genuine Product - President Obama on Live Stem Cells - Video
Contact Information
Available for logged-in reporters only
Newswise Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers.
The gifts bring to $30 million The Broad Foundation's total support of faculty recruitment and basic and translational research at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and at the Center for Inflammatory Bowel Diseases at UCLA's Division of Digestive Diseases.
A $2 million gift to the Broad Stem Cell Research Center adds to The Broad Foundation's original 2007 gift of $20 million, which has supported faculty and research and launched the Innovation Award program, which furthers cutting-edge research at the center by giving UCLA stem cell scientists "seed funding" for their research projects. The new gift will enable the continuation of the award program, which has yielded a 10-to-1 return on investment with grantees securing additional funding from other agencies, including the National Institutes of Health and more than $200 million in total grants from the California Institute for Regenerative Medicine, the state's stem cell agency.
"The Broads' generous support has been essential to the development of new therapies that are currently in, or very near, clinical trials for treating blindness, sickle cell disease and cancer," said Dr. Owen Witte, director of the Broad Stem Cell Research Center. "The Broad Stem Cell Research Center's work, supported by critical philanthropic and other resources, is quickly being translated from basic scientific discoveries into new cellular therapies that will change the practice of medicine and offer future treatment options for diseases thought to be incurable, such as muscular dystrophy, autism and AIDS."
The $2 million gift to the Division of Digestive Diseases builds on nearly $6 million in previous commitments from The Broad Foundation since 2003.
The gifts have enabled the division to develop a comprehensive research and clinical enterprise focused on inflammatory bowel disease, one of only a few such centers in the world. Earning a multifold return for The Broad Foundation's initial investments, these grants have enabled investigators to secure $11 million in funding from pharmaceutical companies, the National Institutes of Health and nonprofit foundations.
In addition, The Broad Foundation's Broad Medical Research Program has provided more than $600,000 in grants to UCLA researchers over the past decade for the study of inflammatory bowel disease.
The new gift will support the Center for Inflammatory Bowel Diseases and research led by Dr. Charalabos "Harry" Pothoulakis, the center's director. Pothoulakis' team conducts research aimed at identifying the molecular mechanisms involved in the development of this group of chronic debilitating diseases, for which there is no cure.
See more here:
$4 Million from Eli and Edythe Broad Foundation Will Support UCLA Research
Beware of fake medicines and advertisements touting the purported miracles that stem cell therapy can do. This was the warning aired by former health secretary Esperanza Cabral at the Kapihan sa Manila at the Diamond Hotel last Monday.
Contrary to what the ads claim, she said, stem cell therapy has not been scientifically proven to cure any disease or make anyone young again. It has been successful in a very few experiments, which is the reason quack doctors are taking advantage of it to make exaggerated claims that the therapy can cure the deadliest diseases known to man.
The Food and Drug Administration (FDA) very recently issued a similar warning against it.
Stem cell therapy is the process of injecting into patients young cells taken from humans or sheep. The theory is that the young cells will rejuvenate the old cells of the patients and make them young again and cure whatever diseases they have. Although experiments are being conducted, no such results have been achieved. But that does not prevent foreign quack doctors from coming here and making all those exaggerated claims. Sadly, they are aided by some Filipino doctors.
The reason is that in countries like the Philippines where the people are suckers for miracle cures, stem cell therapyand other miracle curesis like a gold mine.
Aging millionaires looking for the fountain of youth pay a lot of money to undergo stem cell therapy. Patients with terminal illnesses like cancer, in a desperate search for a cure, also fall victim to the sales talk and word-of-mouth yarns of so-and-so being cured by the therapy.
But they get neither younger nor cured. And the quack doctors run laughing with their patients money all the way to the bank.
A friend told me that he had gone abroad to have stem cell therapy. He said he felt better and stronger after the treatment. Look at me, dont I look younger? he said.
I looked at him. He didnt look a minute younger and in fact looked the same as when I last saw him, maybe even older.
My wife said I look younger, he said. It was his wife who had convinced him to have the stem cell therapy.
See the article here:
Dont be fooled by quacks and fake meds
Body Renewal with Luminesce Adult Stem Cells
FranchiseStemcell Body Renewal with Luminesce Adult Stem Cells from Jeunesse Global.
By: Franchise StemCell
More here:
Body Renewal with Luminesce Adult Stem Cells - Video
A service dog that has come from the brink of death and back was in Terry on Wednesday to receive cutting-edge stem cell therapy.
Davis Hawn said his dog, Booster, saved his life and now he's working to return the favor.
"With Booster by my side, I greet each day knowing we can change the world for the better," Hawn said.
Together, Hawn and Booster helped foster international relations by appearing on TV in Cuba. They reassured Thai orphans infected with the HIV virus that life will be OK and they are loved. The list of accomplishments continued to grow until Booster developed hip dysplasia.
"When Booster couldn't get off the floor, I couldn't get out of bed," said Hawn, who suffers from depression. "Just as assuredly as God put Booster into my life, He again answered the call when I read about the modern day marvel of stem-cell implantation."
Medivet America, a global leader in veterinary science with more than 1,000 clinics in 28 countries, learned of Booster's plight and jumped in to help.
"They arranged to perform a procedure in which they injected Booster's own stem cells into his hips and got him back up and running again," Hawn said. "When I went to pay the bill, they refused to accept payment. I like to say that God paid the bill."
In January 2013, Booster again faced a health battle. He was diagnosed with squamous cell carcinoma and given three weeks to live. An aggressive tumor had eaten through Booster's skull cap and left him writhing in pain. In an effort to save Booster's life, Hawn moved to Florida where the University of Florida operated on Booster and a referral clinic performed radiation therapy.
The University of Minnesota took a piece of the tumor that was removed from Booster and used it to developed the first vaccine for squamous cell carcinoma in dogs.
Booster is now a cancer survivor.
See original here:
Service dog receives cutting-edge stem cell therapy
Stem Sport - Faster Recovery With Nutrition For Your Own Stem Cells
http://www.YourOwnStemCells.Info..........................Find out how a natural supplement will help you recover faster after exercise or an injury. Increase strength,...
By: Linn Fuller
Read the rest here:
Stem Sport - Faster Recovery With Nutrition For Your Own Stem Cells - Video
18 hours ago Cells with activated Wnt can no longer be reprogrammed (in green) are located on the periphery; cells that can be reprogrammed are aggregated anad can be seen in the center of the image (in red) Credit: CRG
In 2012, John B. Gurdon and Shinya Yamakana were awarded the Nobel Prize in medicine for discovering that adult cells can be reprogrammed into pluripotent ones (iPS); the cells obtained are capable of behaving in a similar way to embryonic stem cells, and hence have enormous potential for regenerative medicine.
However, although there are many research groups around the world studying this process, it is still not completely understood, it is not totally efficient, and it is not safe enough to be used as the basis for a new cell therapy.
Now, researchers at the Centre for Genomic Regulation (CRG) in Barcelona have taken a very important step towards understanding cell reprogramming and its efficiency: they have discovered the key role of the Wnt signalling pathway in transforming adult cells into iPS cells.
"Generally, transcription factors are used to try to increase or decrease the cell reprogramming process. We have discovered that we can increase the efficiency of the process by inhibiting the Wnt route", explains Francesco Aulicino, a PhD student in the Reprogramming and Regeneration group, led by Maria Pia Cosma and co-author of the study that has just been published in Stem Cell Reports.
The Wnt signaling pathway is a series of biochemical reactions that are produced in cells. In frogs or lizards, for example, these reactions are those that allow their extremities to regenerate if the animal suffers an injury. Although in general, humans and mammals have lost this regenerative capacity, the Wnt pathway is involved in numerous processes during embryonic development and cell fusion.
As it is in reprogramming. The researchers have studied how the Wnt route behaves throughout the entire process of transforming cells into iPS cells, which usually lasts two weeks. It is a very dynamic process that produces oscillations from the pathway, which is not active all the time. "We have seen that there are two phases and that in each one of them, Wnt fulfils a different function. And we have shown that by inhibiting it at the beginning of the process and activating it at the end we can increase the efficiency of reprogramming and obtain a larger number of pluripotent cells", indicates Ilda Theka, also a PhD student in Pia Cosma's group and a co-author of the article.
To artificially control the pathway, the group has employed a chemical molecule, Iwp2, which is a Wnt secretion inhibitor that does not permanently alter the cells, something which other research into reprogramming using different factors has still has not been able to acheive.
They have also seen that the exact moment when the Wnt pathway is activated is crucial. Doing it too early, makes the the cells begin to differentiate, for example into neurones or endodermal cells, and they are not reprogrammed.
"It is a very important and an innovative advance in the field of cell reprogramming, because until now this was a very inefficient process. There are many groups trying to understand the mechanism by which adult cells become pluripotent, and what blocks that process and makes only a small percentage of cells end up being reprogrammed. We are providing information on why it happens", says Theka.
Originally posted here:
One step closer to cell reprogramming
Knee arthritis 9 months after stem cell therapy by Dr Harry Adelson
Carol describes her outcome from stem cell therapy by Dr Harry Adelson for her arthritic knee http://www.docereclinics.com.
By: Harry Adelson, N.D.
More:
Knee arthritis 9 months after stem cell therapy by Dr Harry Adelson - Video
PUBLIC RELEASE DATE:
6-May-2014
Contact: Sally Stewart sally.stewart@cshs.org 310-248-6566 Cedars-Sinai Medical Center
LOS ANGELES (EMBARGOED UNTIL NOON ET ON MAY 6, 2014) Investigators at the Cedars-Sinai Heart Institute whose previous research showed that cardiac stem cell therapy reduces scarring and regenerates healthy tissue after a heart attack in humans have identified components of those stem cells responsible for the beneficial effects.
In a series of laboratory and lab animal studies, Heart Institute researchers found that exosomes, tiny membrane-enclosed "bubbles" involved in cell-to-cell communication, convey messages that reduce cell death, promote growth of new heart muscle cells and encourage the development of healthy blood vessels.
"Exosomes were first described in the mid-1980s, but we only now are beginning to appreciate their potential as therapeutic agents. We have found that exosomes and the cargo they contain are crucial mediators of stem cell-based heart regeneration, and we believe this might lead to an even more refined therapy using the 'active ingredient' instead of the entire stem cell," said Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and a pioneer in developing investigational cardiac stem cell treatments.
"The concept of exosome therapy is interesting because it could potentially shift our strategy from living-cell transplantation to the use of a non-living agent," he added. "Stem cells must be carefully preserved to keep them alive and functioning until the time of transplant, and there are some risks involved in cell transplantation. In contrast, exosome therapy may be safer and simpler and based on a product with a longer shelf life."
In lab experiments, the researchers isolated exosomes from specialized human cardiac stem cells and found that exosomes alone had the same beneficial effects as stem cells. Exosomes also produced the same post-heart attack benefits in mice, decreasing scar size, increasing healthy heart tissue and reducing levels of chemicals that lead to inflammation. Even when exosomes were injected in mice after heart attack scars were well-established, and traditionally viewed as "irreversible," they brought about multiple structural and functional benefits.
Exosomes transport small pieces of genetic material, called microRNAs, that enable cells to communicate with neighboring cells to change their behavior. The researchers pinpointed one such microRNA one that is especially plentiful in cardiac stem cell exosomes as responsible for some of the benefits. It is likely, they believe, that this and other microRNAs in the exosomes work together to produce the regenerative effects.
"The exosomes appear to contain the signaling information needed to regenerate healthy heart tissue, they are naturally able to permeate cells, and they have a coating that protects their payloads from degradation as they shuttle from cell to cell," said Marbn, senior author of an article in the May 6, 2014 Stem Cell Reports. "Injecting exosomes derived from specialized cardiac stem cells may be an attractive alternative to the transplantation of living cells."
Original post:
Cedars-Sinai researchers identify how heart stem cells orchestrate regeneration
Stem Cells from Humans
PENNSYLVANIA - For the first time ever, cloning technologies are being used to make stem cells that are genetically matched to adult patients. Of course scie...
By: NextNewsNetwork
See the original post here:
Stem Cells from Humans - Video